Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Next Previous
Trial Profile

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesdopetam (Primary)
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Integrative Research Laboratories

Most Recent Events

  • 22 Mar 2024 According to an IRLAB media release, company today announced the receipt of written minutes from a recent End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration, FDA. The minutes confirm the previously communicated positive verbal feedback from the meeting. At the End-of-Phase 2 meeting with the FDA, aspects related to all parts of the development plan for mesdopetam, including the design of a Phase III program.
  • 22 Feb 2024 According to an IRLAB media release, the company completed End-of-Phase 2 meeting with the US Food and Drug administration(FDA),aspects related to the Phase III program with mesdopetam were discussed.
  • 27 Aug 2019 According to an IRLAB media release, full results of this study will be published in an international scientific journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top